2021
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
Weishaar K, Wright Z, Rosenberg M, Post G, McDaniel J, Clifford C, Phillips B, Bergman P, Randall E, Avery A, Thamm D, Hull A, Gust C, Donoghue A. Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma. Journal Of Veterinary Internal Medicine 2021, 36: 215-226. PMID: 34952995, PMCID: PMC8783351, DOI: 10.1111/jvim.16341.Peer-Reviewed Original ResearchConceptsBest overall response ratePlacebo-treated dogsProgression-free survivalOverall response rateAdverse eventsResponse rateMedian progression-free survivalCommon adverse eventsPlacebo-controlled studySerious adverse eventsNovel chemotherapy agentsClient-owned dogsTreatment of lymphomaRAB groupSignificant antitumor efficacyStudy endpointMulticentric lymphomaTreatment completionChemotherapy agentsPercent progressionSafety dataLast treatmentClinical importanceLymphomaRabacfosadineThe Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
Post G, Lustgarten J. The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study. Topics In Companion Animal Medicine 2021, 46: 100616. PMID: 34864255, DOI: 10.1016/j.tcam.2021.100616.Peer-Reviewed Original ResearchConceptsOligo-FucoidanComplete blood countLife metricsLife scoresDouble-blinded studyMinimal adverse side effectsCase-control studyPlacebo control groupAdverse side effectsSignificant differencesQuality of lifeDiagnosis of cancerSerum biochemical parametersSerum biochemistry profilePlacebo groupUndergoing ChemotherapyProspective studyPhysical examinationBlood countCancer CenterFucoidan groupBlinded cliniciansLife QuestionnaireVeterinary patientsSide effects
2020
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials
Saba C, Clifford C, Burgess K, Phillips B, Vail D, Wright Z, Curran K, Fan T, Elmslie R, Post G, Thamm D. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Veterinary And Comparative Oncology 2020, 18: 763-769. PMID: 32346934, PMCID: PMC7754483, DOI: 10.1111/vco.12605.Peer-Reviewed Original ResearchConceptsLarge cell lymphomaCell lymphomaOverall median progression-free intervalMedian progression-free intervalAdverse event evaluationAdverse event profileMinute intravenous infusionProgression-free intervalProspective clinical trialsT-cell immunophenotypeOverall response rateSubstantial antitumour activityDrug-resistant relapseRelapsed subjectsSupportive treatmentUntreated dogsUntreated lymphomaConcurrent corticosteroidsDosage adjustmentPulmonary fibrosisEvent profileGastrointestinal originGroup criteriaIntravenous infusionInferior outcomesConcurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Cawley J, Wright Z, Meleo K, Post G, Clifford C, Vickery K, Vail D, Bergman P, Thamm D. Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal Of Veterinary Internal Medicine 2020, 34: 882-889. PMID: 32064697, PMCID: PMC7096650, DOI: 10.1111/jvim.15723.Peer-Reviewed Original ResearchConceptsMedian progression-free survival timeOverall response rateComplete responseMulticentric lymphomaAdverse eventsL-asparaginaseProspective single-arm clinical trialProgression-free survival timeSingle-arm clinical trialNegative prognostic factorRelapse of lymphomaTreatment of lymphomaNovel antineoplastic agentPrognostic factorsChemotherapy protocolsClinical trialsRabacfosadineSurvival timeIU/Response rateClinical importanceLymphomaMultivariate analysisAntineoplastic agentsConcurrent use
2018
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
Hendricks W, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery N, Washington M, Aldrich J, Neff M, Huentelman M, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent J. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLOS Genetics 2018, 14: e1007589. PMID: 30188888, PMCID: PMC6126841, DOI: 10.1371/journal.pgen.1007589.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell CycleCell ProliferationComparative Genomic HybridizationDNA Mutational AnalysisDog DiseasesDogsFemaleMaleMelanomaMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Receptor-Like Protein Tyrosine Phosphatases, Class 3Signal TransductionSkin NeoplasmsTissue Array AnalysisConceptsLow point mutation ratePowerful comparative modelComparative genomic analysisCell cycle controlPoint mutation rateSingle nucleotide polymorphism arrayNucleotide polymorphism arrayWhole-genome sequencingArray comparative genomic hybridizationHuman melanomaComparative genomic hybridizationGenomic analysisRNA sequencingCycle controlGenome sequencingMutation rateGenomic landscapePolymorphism arrayCopy numberMutational landscapeMutational signaturesGenomic hybridizationRecurrent alterationsMulti-platform analysisMutations
2017
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research 2017, 23: 2565-2574. PMID: 27815356, PMCID: PMC5418113, DOI: 10.1158/1078-0432.ccr-16-2152.Peer-Reviewed Original ResearchConceptsMast cell tumorsSpontaneous mast cell tumoursMast cell numbersMast cell degranulationCutaneous mast cell numberKIT phosphorylationCell degranulationOpen-label clinical studyBiochemical adverse eventsAcceptable safety profileMetastatic lymph nodesPharmacokinetics/pharmacodynamics profileFuture clinical evaluationClin Cancer ResCell numberDose-dependent mannerObjective responseAdverse eventsLymph nodesMCT patientsClinical effectsClinical toxicityClinical benefitHuman clinical applicationsSafety profileGeographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol
Wilson‐Robles H, Budke C, Miller T, Dervisis N, Novosad A, Wright Z, Thamm D, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T. Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. Veterinary And Comparative Oncology 2017, 15: 1564-1571. PMID: 28419683, DOI: 10.1111/vco.12302.Peer-Reviewed Original ResearchConceptsProgression-free survivalFree survivalMultivariable Cox regression modelsShorter progression-free survivalSurvival of dogsCox regression modelNon-Hodgkin lymphomaCHOP chemotherapyChemotherapy protocolsReferral institutionMedical recordsUnivariate analysisDoxorubicin dosesCanine lymphomaVeterinary oncologyDoxorubicin treatmentGeographical differencesLymphomaDogsSignificant differencesImmunophenotypeSurvivalRegression modelsGeographic differencesUS regionsAlternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
Thamm D, Vail D, Post G, Fan T, Phillips B, Axiak‐Bechtel S, Elmslie R, Klein M, Ruslander D. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. Journal Of Veterinary Internal Medicine 2017, 31: 872-878. PMID: 28370378, PMCID: PMC5435064, DOI: 10.1111/jvim.14700.Peer-Reviewed Original ResearchConceptsProgression-free intervalMulticentric lymphomaComplete responseOverall median progression-free intervalMedian progression-free intervalMulticenter prospective clinical trialSubstantial single-agent activityAdverse effect profileAssessment of remissionMost adverse eventsProspective clinical trialsSingle-agent activityLong-term outcomesOverall response rateCanine multicentric lymphomaDermatologic AEsHematologic AEsClinicopathological evaluationAdverse eventsChemotherapy combinationsCombination chemotherapyTreatment visitsUntreated lymphomaEffect profilePulmonary fibrosis
2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
London C, Gardner H, Mathie T, Stingle N, Portela R, Pennell M, Clifford C, Rosenberg M, Vail D, Williams L, Cronin K, Wilson-Robles H, Borgatti A, Henry C, Bailey D, Locke J, Northrup N, Crawford-Jakubiak M, Gill V, Klein M, Ruslander D, Thamm D, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLOS ONE 2015, 10: e0124889. PMID: 25923466, PMCID: PMC4414350, DOI: 10.1371/journal.pone.0124889.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, MetronomicAmputation, SurgicalAnimalsBone NeoplasmsCarboplatinCyclophosphamideDiarrheaDisease-Free SurvivalDog DiseasesDogsDrug Therapy, CombinationFemaleIndolesKaplan-Meier EstimateMaleNeutropeniaOsteosarcomaPiroxicamProspective StudiesPyrrolesRegression AnalysisTreatment OutcomeConceptsDisease-free intervalMedian disease-free intervalCarboplatin chemotherapyMetastatic diseaseOverall survivalControl dogsMaintenance therapyAppendicular osteosarcomaMedical conditionsSurvival rateTherapy-associated adverse eventsGross metastatic diseaseMedian overall survivalOutcome of dogsProspective clinical trialsYear survival rateMulti-institutional studyPiroxicam therapyCyclophosphamide therapyAdverse eventsPatient demographicsSupportive careStudy entryMetronomic treatmentClinical trialsRecurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone
Smith J, Kiupel M, Farrelly J, Cohen R, Olmsted G, Kirpensteijn J, Brocks B, Post G. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Veterinary And Comparative Oncology 2015, 15: 36-45. PMID: 25643820, DOI: 10.1111/vco.12140.Peer-Reviewed Original ResearchConceptsGrade II mast cell tumorsMast cell tumorsRecurrence rateLow proliferation activitySurgical excisionHistologic marginsKi67 indexCutaneous mast cell tumorsLow Ki67 indexLow AgNOR countsProliferation activityVariable biologic behaviorMedian followAncillary therapyDistant recurrenceLocal recurrenceClinical outcomesCell tumorsBiologic behaviorMast cellsAgNOR countsProliferation markersDogsRecurrenceTumors
2014
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
Roberts N, Zhang L, Janku F, Collins A, Bai R, Staedtke V, Rusk A, Tung D, Miller M, Roix J, Khanna K, Murthy R, Benjamin R, Helgason T, Szvalb A, Bird J, Roy-Chowdhuri S, Zhang H, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein M, Post G, Diaz L, Riggins G, Papadopoulos N, Kinzler K, Vogelstein B, Bettegowda C, Huso D, Varterasian M, Saha S, Zhou S. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Science Translational Medicine 2014, 6: 249ra111. PMID: 25122639, PMCID: PMC4399712, DOI: 10.1126/scitranslmed.3008982.Peer-Reviewed Original ResearchConceptsC. novyi-NT sporesIntratumoral injectionHuman patientsCanine tumorsFurther clinical trialsOrthotopic brain tumor modelC. novyi-NTBrain tumor modelClostridium novyi-NT sporesSpontaneous solid tumorsCommon toxicitiesObjective responsePartial responseAdvanced leiomyosarcomaAntitumor responseClinical trialsHeterogeneous genetic backgroundHuman trialsSolid tumorsBacterial infectionsNeoplastic tissueTumor modelTumorsTherapeutic agentsPatients
2012
Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision
Dank G, Rassnick K, Sokolovsky Y, Garrett L, Post G, Kitchell B, Sellon R, Kleiter M, Northrup N, Segev G. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Veterinary And Comparative Oncology 2012, 12: 78-84. PMID: 22737988, DOI: 10.1111/j.1476-5829.2012.00338.x.Peer-Reviewed Original ResearchConceptsMalignant melanomaOverall median progression-free survivalMedian progression-free survivalProgression-free survival eventsAdjuvant carboplatin chemotherapyCommon oral malignancyMalignant oral melanomasMedian overall survivalProgression-free survivalOral malignant melanomaTreatment of dogsNumber of dosesCanine malignant melanomaCause of deathAdjuvant carboplatinCarboplatin chemotherapyMedian dosageOverall survivalSurgical resectionSystemic therapyLocal recurrenceOral malignanciesSurgical excisionRetrospective studyOral melanomaA Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs
Vail D, von Euler H, Rusk A, Barber L, Clifford C, Elmslie R, Fulton L, Hirschberger J, Klein M, London C, Martano M, McNiel E, Morris J, Northrup N, Phillips B, Polton G, Post G, Rosenberg M, Ruslander D, Sahora A, Siegel S, Thamm D, Westberg S, Winter J, Khanna C. A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs. Journal Of Veterinary Internal Medicine 2012, 26: 598-607. PMID: 22390318, PMCID: PMC3837094, DOI: 10.1111/j.1939-1676.2012.00897.x.Peer-Reviewed Original ResearchConceptsMast cell tumorsAdverse eventsCell tumorsGrade 2Response ratePositive-controlled clinical trialMajority of AEsOverall response rateEarly phase studiesObserved response rateMechanism of actionAvailable TKIsPrimary endpointProspective multicenterSecondary endpointsSafety profileAE profileClinical trialsEffective treatmentPaclitaxel activityClinical importanceCombination protocolMicellar paclitaxelPaclitaxelLomustine
2011
Single‐agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas
Elpiner A, Brodsky E, Hazzah T, Post G. Single‐agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas. Veterinary And Comparative Oncology 2011, 9: 260-268. PMID: 22077406, DOI: 10.1111/j.1476-5829.2011.00262.x.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaGemcitabine chemotherapyMedian progression-free intervalSingle-agent gemcitabine chemotherapyGrade III neutropeniaNonresectable hepatocellular carcinomaSerial abdominal ultrasoundsTolerability of gemcitabineProgression-free intervalMedian survival timeAbdominal ultrasoundIncomplete resectionFree intervalSurvival timeDogsBest treatmentChemotherapyGemcitabineCarcinomaToxicityDaysVomitingNeutropeniaTolerabilityResection
2009
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP‐MA) for the treatment of canine lymphoma
Daters A, Mauldin G, Mauldin G, Brodsky E, Post G. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP‐MA) for the treatment of canine lymphoma. Veterinary And Comparative Oncology 2009, 8: 11-22. PMID: 20230577, DOI: 10.1111/j.1476-5829.2009.00199.x.Peer-Reviewed Original ResearchConceptsMultidrug chemotherapy protocolMulticentric lymphomaMedian survivalChemotherapy protocolsSurvival timeOverall median survivalDose of doxorubicinCanine multicentric lymphomaMitoxantrone dosesOverall remissionSteroid administrationMedian remissionHistorical controlsRemission timeCanine lymphomaLymphomaRemissionMitoxantroneDogsFurther studiesL-asparaginaseSurvivalDoxorubicinDaysHypercalcaemiaAsparaginase and MOPP Treatment of Dogs with Lymphoma
Brodsky E, Maudlin G, Lachowicz J, Post G. Asparaginase and MOPP Treatment of Dogs with Lymphoma. Journal Of Veterinary Internal Medicine 2009, 23: 578-584. PMID: 19645842, DOI: 10.1111/j.1939-1676.2009.0289.x.Peer-Reviewed Original ResearchConceptsOverall survival timeT-cell lymphomaT-cell phenotypeEntire study populationStudy populationSurvival timeMulticentric T-cell lymphomaMedian overall survival timeProgression-free survival timePresence of hypercalcemiaOverall response rateReferral veterinary hospitalAntigen receptor rearrangementMedian PFSMOPP chemotherapyMOPP treatmentPrevious chemotherapyLonger PFSChemotherapy protocolsMulticentric lymphomaRetrospective studyPolymerase chain reactionCytologic diagnosisReceptor rearrangementLymphoma
2004
Acquired amegakaryocytic thrombocytopenia — four cases and a literature review
Lachowicz J, Post G, Moroff S, Mooney S. Acquired amegakaryocytic thrombocytopenia — four cases and a literature review. Journal Of Small Animal Practice 2004, 45: 507-514. PMID: 15515801, DOI: 10.1111/j.1748-5827.2004.tb00197.x.Peer-Reviewed Original ResearchConceptsImmune-mediated diseasesAssociated infectious diseasesPositive antibody titresAntibody titresInitial bone marrow examinationInfectious diseasesBone marrow examinationInitial platelet countMarrow examinationMegakaryocytic hypoplasiaPlatelet countPositive titresPostmortem examinationInfectious organismsMyeloid cell linesDiseaseEhrlichia canisDogsTitresB. burgdorferiPrednisoneCell linesBurgdorferiTreatmentMinimal changes
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003, 9: 2755-68. PMID: 12855656.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDog DiseasesDogsDose-Response Relationship, DrugEnzyme InhibitorsFemaleIndolesInhibitory Concentration 50MaleModels, ChemicalMutationNeoplasmsProto-Oncogene Proteins c-kitPyrrolesReceptor Protein-Tyrosine KinasesReceptors, Vascular Endothelial Growth FactorTime FactorsTomography, X-Ray ComputedConceptsReceptor tyrosine kinase inhibitorsTyrosine kinase inhibitorsGrowth factor receptorKinase inhibitorsSpontaneous malignanciesSpontaneous tumorsSmall molecule receptor tyrosine kinase inhibitorPhase I dose-escalating studyDose-escalating studyMeasurable objective responseSimilarities of canineVascular endothelial growth factor receptorStandard treatment regimensFactor receptorPhase I trialEndothelial growth factor receptorOverall response rateSoft tissue sarcomasPlatelet-derived growth factor receptorMast cell tumorsVariety of cancersStable diseaseObjective responseOral therapyProgressive diseaseGastrointestinal Leiomyosarcoma in 14 Dogs
Cohen M, Post G, Wright J. Gastrointestinal Leiomyosarcoma in 14 Dogs. Journal Of Veterinary Internal Medicine 2003, 17: 107-110. PMID: 12564735, DOI: 10.1111/j.1939-1676.2003.tb01331.x.Peer-Reviewed Original ResearchConceptsImmediate postoperative periodIntestinal leiomyosarcomaPostoperative periodTime of surgeryCommon clinical signsClinical characteristic featuresLong-term survivalMedian survivalRetrospective reviewSurgical excisionGastrointestinal leiomyosarcomaLonger survivalClinical signsMean survivalSurvival rateLeiomyosarcomaDogsSurvivalSurgeryMonthsPolyuriaHypoglycemiaPolydipsiaAnemiaMetastasis
2001
Clinicopathologic and Electron Microscopic Study of Cutaneous Neuroendocrine (Merkel Cell) Carcinoma in a Cat with Comparisons to Human and Canine Tumors
Patnaik A, Post G, Erlandson R. Clinicopathologic and Electron Microscopic Study of Cutaneous Neuroendocrine (Merkel Cell) Carcinoma in a Cat with Comparisons to Human and Canine Tumors. Veterinary Pathology 2001, 38: 553-556. PMID: 11572564, DOI: 10.1354/vp.38-5-553.Peer-Reviewed Original ResearchConceptsMerkel cell tumorNeuroendocrine carcinomaCell tumorsMalignant neuroendocrine carcinomasCutaneous neuroendocrine carcinomaElectron microscopic findingsBasis of morphologicMaine Coon catsSurgical excisionMicroscopic findingsTumor malignancyCanine tumorsBenign natureTumorsMalignancyElectron microscopic studyCarcinomaCatsMicroscopic studyClinicopathologicHumansExcisionDiagnosisDogs